Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Published 31 October 2008, doi:10.1136/bmj.a2034
Cite this as: BMJ 2008;337:a2034
Yes, but to what extent is unclear
| The first 150 words of the full text of this article appear below. |
Patients preferences are important. Where treatment choices have different and well understood outcomes, what matters most when deciding which treatment is best is the patients preference. The intriguing question is whether strong treatment preferences can also affect outcomes—that is, can the preferences themselves exert a therapeutic effect over and above the anticipated effects of compliance and attrition, and if so, by how much? We know very little about this area. In the linked study (doi:10.1136/bmj.a1864), the Preference Collaborative Review Group reviews the effects of patient preferences on attrition and outcomes in trials of patients preferences using a meta-analysis of individual patient data.1
We know that the placebo effect can be profound. Its most plausible mechanism of action involves belief in an effect, and this must relate strongly to preferences.2 But a double blind trial of placebo versus nothing is needed to identify a placebo effect. Some meta-analyses have
Klim McPherson, visiting professor of public health epidemiology
1 Nuffield Department of Obstetrics and Gynaecology, Oxford University, Womens Centre, John Radcliffe Hospital, Headington, Oxford OX3 9DU
klim.mcpherson@obs-gyn.ox.ac.uk
Read all Rapid Responses